Site is Being Upgraded

Heart attack

June 19, 2018

Natural product-derived therapy for cardiac hypertrophy and fibrosis: A pharmaceutical mixture encompassing Sulforaphane, Myricitrin and Aspalathin (SMA) decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 19/June/2017, 10.36 pm

Introduction: What they say: A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular […]
June 9, 2018

CD-24-based therapy for Myocardial Infarction: CD-24 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up regulation of PNUTS, 9/June/2018, 10.57 pm

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of […]
June 9, 2018

CD24-based therapy for cardiomyocyte proliferation and heart regeneration: Cluster of Differentiation(CD-24) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up regulation of its target gene, 9/June/2018, 10.41 pm,

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory […]
June 1, 2018

Combinatorial therapy for cardiomyocyte proliferation and heart regeneration: A pharmaceutical mixture encompassing L-Malate, Lithium and Imidazopyridine derivative (X22) (MLX22) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up regulation of its target gene, 1/June/2018, 10.51 pm

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory […]